Fiche du document
18 janvier 2023
- doi: 10.53738/REVMED.2023.19.809-10.77
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.809-10.77
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36660842
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7306A7EE35723
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-07-18 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Diseases and hygiene Pneumonia, Interstitial Hamman-Rich syndrome Fibrosing alveolitis Pneumonitis, Interstitial Interstitial pneumonia Interstitial fibrosis of the lung Interstitial pneumonitis Alveolitis, Fibrosing Diffuse interstitial pulmonary fibrosis Lungs--Fibrosis Diffuse fibrosing alveolitis Administration Sickness Human beings--Diseases Morbidity Illness Sicknesses IllnessesCiter ce document
M. Kolb et al., « Pneumologie : ce qui a changé en 2022 [Pneumology: what's new in 2022] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.809-10.77
Métriques
Partage / Export
Résumé
This selection of pneumological novelties of the year 2022 is not limited to pharmacological acquisitions but also includes progress in diagnostic strategies and the global management of respiratory diseases. We have chosen three pneumological issues. As cannabis is the most consumed illegal substance in Switzerland, it is important to know its impact on pulmonary physiology. An update of the international guidelines on pulmonary fibrosis as well as the European guidelines on pulmonary hypertension provides practical answers to the many clinical problems encountered in the management of these diseases. The key messages from these two consensus documents are reported here.